|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 红细胞分布宽度作为心力衰竭预后的新标记物:来自CHARM计划和Duke数据库的资料显示文摘目的:确定慢性心力衰竭患者风险的可能的新实验室标记物。背景:尽管已有多种心力衰竭预后指标被提出,但对常规实验室检查价值的系统评价尚未见报道。 | Felker G.M. Allen L.A. Pocock S.J. 孙凯 | 2007 | 世界核心医学期刊文摘(心脏病学分册)2007,,10: | 28 |
| 2 | 在没有危险因素的情况下,正常的低密度脂蛋白胆固醇水平与亚临床动脉粥样硬化相关显示文摘普遍认为缺乏心血管病危险因素(cardiovascular risk factors,CVRF)人群的动脉粥样硬化发生风险低,然而,无CVRF的个体仍然有心血管事件发生。为了确定无CVRF个体中亚临床动脉粥样硬化的预测因子, | Fernández-Friera L Fuster V López-Melgar B Oliva B García-Ruiz JM Mendiguren J Bueno H Pocock S Ibánez B Fernández-Ortiz A Sanz J 刘莉 叶鹏 | 2017 | 中华高血压杂志2017,25,12: | 17 |
| 3 | 加强流行病学中观察性研究报告质量(STROBE)声明:观察性研究报告规范显示文摘很多生物医学研究都是观察性的。但对这类研究的报告却通常不完整,从而限制了对其优缺点及普适性的评价。“加强流行病学中观察性研究报告质量(STROBE)”工作组针对一篇完整明确的观察性研究报告应包括的内容提供了一套建议。建议涵盖了流行病学研究的三种主要设计类型:队列设计、病例对照设计和横断面设计。2004年9月,我们召开了为期2天的研讨会,与会的方法学专家、研究人员和期刊编辑共同起草了一份观察性研究报告应纳入的条目清单草案。此后,又通过协调小组数次会议及与有关人员电子邮件讨论等对该草案进行了修改,纳入了经验性证据和方法学方面的意见。通过研讨会及之后反复的咨询和修订,我们制定出了一个包含22个条目的清单(STROBE声明),分为论文的题目、摘要、引言、方法、结果和讨论等部分。其中18个条目适用于所有三种主要的观察性研究设计,其余4个条目则专门用于队列、病例一对照或横断面设计。详细的解释和示范文件已另行发表,在《公共科学图书馆一医学》(PLoS Medicine)、《内科学年报》(Annalsof Internal Medicine)和《流行病学》(Epidemiology)的网站可以免费获得。我们希望STROBE声明能有助于改善观察性研究报告的质量。 | Erikvon Elm Douglas G Altman Matthias Egger Stuart J Pocock Peter C G tzsche Jan P Vandenbroucke 赵乐(译) 邹光勇(审) 杜怀东(审) | 2008 | 世界临床医学2008,2,1: | 12 |
| 4 | Red Cell Distribution Width as a Novel Prognostic Marker in Heart Failure显示文摘 | G. Michael Felker Larry A. Allen Stuart J. Pocock Linda K. Shaw John J.V. McMurray Marc A. Pfeffer Karl Swedberg Duolao Wang Salim Yusuf Eric L. Michelson Christopher B. Granger | 2007 | Journal of the American College of Cardiology2007,,1: | 5 |
| 5 | 基于一个大型随机试验预测稳定性心绞痛队列患者死亡、心肌梗死和卒中的危险评分显示文摘目的对需要抗心绞痛治疗并且左心室功能代偿症状稳定的心绞痛患者建立预测全因死亡、心肌梗死和导致致残性卒中的复合危险评分。设计大型多中心临床试验数据的多变量Cox回归分析。背景西欧、以色列、加拿大、澳大利亚和新西兰的心脏专科门诊患者。入选者7311例具有全部需要资料的患者被入选。主要结局的测量指标平均随访4.9年时间内所有原因的死亡、心肌梗死或者致残性卒中。结果1063例患者发生任何原因死亡或者持久性心肌梗死或者致残性卒中。这些复合终点的5年危险性在危险性最低的十分位患者为4%,而在危险性最高的十分位患者为35%。危险评分结合16项临床常规变量的降序排序是:年龄、左心室射血分数、吸烟、白细胞计数、糖尿病、随机血糖浓度、肌酐浓度、既往卒中病史、1周至少1次心绞痛发作、冠状动脉造影发现(如果能够获得)、降脂治疗、QT间期、收缩期血压≥150mmHg、抗心绞痛药物数量、陈旧性心肌梗死以及性别。把这个模型分别应用于任何原因所致的死亡、心肌梗死和卒中进行预测评估,所得的结果相似。危险评分似乎不能预测事件性质(39%的死亡、46%心肌梗死以及15%致残性卒中)或者冠状动脉造影或血管重建率(占29%的患者)。结论该危险评分对客观地决定稳定性心绞痛患者进一步治疗措施以减少重要预后事件发生是有帮助的。该危险评分同样可以用于将来的计划性试验。 | Tim C Clayton Stuart J Pocock Jacobus Lubsen Zoltán Vokó Bridget-Anne Kirwan Keith A A Fox Philip A Poole-Wilson | 2006 | 英国医学杂志中文版2006,9,1: | 2 |
| 6 | Bone mineral density,body mass index and cigarette smoking among Iranian women:implications for prevention显示文摘 | BAHEIRAEI A POCOCK N A EISMAN J A | 2005 | BMC Musculoskelet Disord2005,24,6: | 1 |
| 7 | Red cell distri- bution width as a novel prognostic marker in heart failure: data from the Charm Program and the Duke Databank显示文摘 | FELKER GM ALLEN LA POCOCK SJ | 2007 | J Am Coil Cardiol2007,50,: | 1 |
| 8 | Red cell distribution width as a novel prognostic marker in heart failure:data from the CHARM Program and the Duke Databank显示文摘 | Felker GM Allen LA Pocock SJ | | 0,,1: | 1 |
| 9 | Influenee of yeast strain on binding of sulphur dioxide in wines, and on its formation during fermentation 显示文摘 | Rankine B C Pocock K F | 1962 | J Sei Food Agile1962,20,2: | 1 |
| 10 | Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes ( RECORD ): study design and protocol 显示文摘 | Home PD Pocock SJ Beck-Nielsen H | 2005 | Diabetologia2005,48,9: | 1 |
| 11 | Identification of risk factors in hypertensive patients: contribution of randomized controlled trials through an individual patient database显示文摘 | Gueyffier F Boissel JP Pocock S | 1999 | Circulation1999,100,18: | 1 |
| 12 | High strength steel use in Australia, Japan and the US显示文摘 | Pocock G | 2006 | The Structural Engineer2006,84,21: | 1 |
| 13 | Issues in the reporting of epidemiological studies:a survey of recent practice显示文摘 | Pocock SJ Collier TJ Dandreo KJ | 2004 | Brit Med J2004,329,7471: | 1 |
| 14 | Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles显示文摘 | David Cunningham Eliza A Hawkes Andrew Jack Wendi Qian Paul Smith Paul Mouncey Christopher Pocock Kirit M Ardeshna John A Radford Andrew McMillan John Davies Deborah Turner Anton Kruger Peter Johnson Joanna Gambell David Linch | 2013 | The Lancet2013,,9880: | 1 |
| 15 | Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank显示文摘 | Felker GM Allen LA Pocock SJ | | J Am Coil Cardiol0,50,1: | 1 |
| 16 | Rac GTPases:domain-specific functions in neuronal development显示文摘Understanding fundamental mechanisms governing axon outgrowth and guidance can inform the development of therapeutic strategies to restore neuronal function damaged though injury or disease. Axons navigate the extracellular environment by responding to guidance cues that bind to cell surface receptors to relay information intracellularly via Rho GTPase family members, including the Rac GTPases. | Steffen Norgaard Roger Pocock | 2019 | Neural Regeneration Research2019,14,8: | 1 |
| 17 | A novel phosphodiesterase type 4 inhibitor, HT-0712,enhances rehabilitation-dependent motor recovery and eortical reorganization after focal cortical ischemia 显示文摘 | MacDonald E Vander Lee H Pocock D | 2007 | Neurorehabil Neural Repair2007,21,6: | 1 |
| 18 | Associations of major bleeding and myo- cardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial 显示文摘 | Mehran R Pocock SJ Stone GW | 2009 | Eur Heart J2009,30,12: | 1 |
| 19 | Rosiglita- zone evaluated for cardiovascular outcomes in oral agent combina- tion therapy for type 2 diabetes (RECORD) : a multicentre, ran- domized, open-label trial 显示文摘 | HOME PD POCOCK SJ BECK-NIELSEN H | 2009 | Lancet2009,373,9681: | 1 |
| 20 | Red cell distribution width as a novel prognostic marker in heart failure:Data from the CHARM program and the duke databank显示文摘 | FELKER G M ALLEN L A POCOCK S J | 2007 | J Am Coll Cardiol2007,50,: | 1 |